Most evaluated drugs have an active comparator but studies comparing them directly are not as common. ICs could be included in more reports along with quality control criteria.

Electronic prescription is a powerful tool, and one that in this work was shown to decrease medication-, diet-, and nursing care-related errors in a highly significant way; however, it should be developed and maintained in order to achieve safety and effectiveness as required by drug usage.

The work carried out by the GENESIS group has enabled Spanish hospitals to share their drug assessment reports and making them more complete, although there are still some aspects that can be improved.

The presence of oxaliplatin-associated neurotoxicity and its distribution based on its severity was similar to rates published in the literature. The number of patients requiring a change in the oxaliplatin prescription could justify the need for studies that assess the clinical consequences of these modifications. We believe that effective strategies for neurological protection need to be developed in order to guarantee the safety and quality of life in these patients.

Background and importance First-generation Janus kinase inhibitors (JAKi), tofacitinib and baricitinib, are approved in adults with moderately to severely active rheumatoid arthritis (RA) who have not responded or tolerated previous treatment lines. Real clinical data about persistence and therapeutic adherence to these treatments is scarce. Aim and objectives (i) To assess and compare first-generation JAKi persistence in clinical practice. (ii) To compare whether therapeutic adherence to tofacitinib and baricitinib influences treatment persistence. Material and methods This was a retrospective study which included all RA patients treated with tofacitinib and/or baricitinib between October 2017 and May 2021 in a tertiary hospital. Demographic, clinical and pharmacological data were collected from electronic medical and pharmacy claim records. Kaplan-Meier survival analyses and log rank test were performed to calculate and compare treatment persistence. We assessed drug adherence with the medication possession ratio (MPR). Effect of therapeutic adherence on treatment persistence was evaluated with a linear regression model. Statistical analyses were performed using Stata 15 software. Results We included 136 cases (61 were treated with tofacitinib (44.9%) and 75 with baricitinib (55.1%)) corresponding to 105 RA patients. They were mostly women (86.7%) with a mean age (±SD) of 63 (±13) years. At treatment initiation, patients had a mean DAS28-ESR (±SD) of 5.1±1.2. Study patients had previously received a median (range) of 3 (0-8) biologic agents for RA.During the study period, 40 (29.4%) and 38 (27.9%) patients treated with tofacitinib and baricitinib, respectively, discontinued the treatment.Mean treatment persistence was 363 days (95% CI 2 to 1282) in the tofacitinib group and 406 days (95% CI 8 to 1300) in the baricitinib group. There were no statistically differences in treatment survival (HR 1.01; 95% CI 0.59 to 1.71; p=0.97).Mean MPR was 91.0% in both groups. There was no correlation between therapeutic adherence and persistence (p=0.21). Conclusion and relevanceOur results show no significant differences in treatment persistence and adherence between tofacitinib and baricitinib patients. In our cohort, medication adherence was high and did not influence treatment persistence.